ClinicalTrials.gg
CompletedNCT01649765PLUTOUpdated Apr 20, 2026Results posted

Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy

A Phase 2 interventional study of Belimumab 10 mg/kg and Placebo in Systemic Lupus Erythematosus, sponsored by GlaxoSmithKline. Completed at 32 sites in 10 countries. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-04-20.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
93
Allocation
Randomized
Ages
5 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 36 studies testing belimumab in Lupus Erythematosus, Systemic — 4 open to participants now, 7 under way, none of them phase 3. belimumab · Lupus Erythematosus, Systemic.

Enrollment
17th of 36
93 · median 81
Started
2012
with 4 others
Phase 2
8 of 36
2 open now
Registered
17th of 36
by date
Lead sponsor
13 of 36
GlaxoSmithKline

Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, this one is the 17th largest by enrollment, is one of 5 that started in 2012, is one of 8 in phase 2, and was the 17th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

4 of the 36 studies testing belimumab in Lupus Erythematosus, Systemic are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About belimumab

belimumab: first FDA approval 2011 (BENLYSTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 5 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing belimumab in Lupus Erythematosus, Systemic, or all of them as a file.
02

Study summary

This is a multi-center study to evaluate the safety, pharmacokinetics, and efficacy of belimumab intravenous (IV) in pediatric patients 5 to 17 years of age with active systemic lupus erythematosus

Read the detailed description

This is a multi-center study to evaluate the safety, pharmacokinetics, and efficacy of belimumab intravenous (IV) in pediatric patients 5 to 17 years of age with active systemic lupus erythematosus (SELENA SLEDAI score ≥ 6). The study will consist of three phases: a 52-week randomized, placebo-controlled, double-blind phase; a long term open label continuation phase; and a long term safety follow up phase. The long term open label continuation and safety follow up periods will continue for at least 5 years and possibly up to 10 years from a subject's initial treatment with belimumab. Enrolment will be staggered by age cohorts to allow safety and PK interim analyses. Subjects will be randomized to belimumab 10mg/kg or placebo IV monthly dosing while continuing to receive background standard therapy throughout the study. An independent data monitoring committee (IDMC) will monitor the study as it progresses.

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • SLE Flare Index
  • SRI
  • belimumab
  • efficacy
  • safety
  • B lymphocyte
  • BLyS
  • SELENA SLEDAI
  • BILAG
  • Lupus
  • Systemic Lupus Erythematosus (SLE)
  • PGA
  • Pharmacokinetics
  • placebo
  • PRINTO
04

Who can participate

Ages eligible
5 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 5 years to 17 years of age at enrollment
  • Have a clinical diagnosis of SLE according to the American College of Rheumatology (ACR) classification criteria.
  • Have active SLE disease (SELENA SLEDAI score ≥ 6).
  • Have positive anti-nuclear antibody (ANA) test results.
  • Are on a stable SLE treatment regimen at a fixed dose for a period of at least 30 days prior to Day 0.
  • Females of childbearing age are willing to use appropriate
  • Subject age appropriate assent and parent or legal guardian to participate

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing.
  • Have received treatment with belimumab (BENLYSTA®) at any time. (BENLYSTA® is a registered trademark of the GSK group of companies.)
  • Treatment with any B cell targeted therapy (for example, rituximab) or an biological agent in the past year.
  • Have received anti-TNF therapy; Interleukin-1 receptor antagonist; IVIG; or plasmapheresis within 90 days of Day 0.
  • Have received high dose prednisone or equivalent (>1.5mg/kg/day) within 60 days of baseline.
  • Have received intravenous (IV) cyclophosphamide within 60 days of Day 0.
  • Have received any new /immunomodulatory agent, anti-malarial agent within 60 days of baseline.
  • Have severe lupus kidney disease.
  • Have active central nervous system (CNS) lupus.
  • Have had a major organ transplant.
  • Have significant unstable or uncontrolled acute or chronic diseases or conditions not due to SLE.
  • Have a planned surgical procedure.
  • History of malignant neoplasm within the last 5 years.
  • Have required management of acute or chronic infections in the past 60 days.
  • Have current drug or alcohol abuse or dependence.
  • Have a historically positive test, or test positive at screening for , , or .
  • Have an IgA deficiency.
  • Have severe laboratory abnormalities.
  • Have had anaphylactic reaction to X-ray contrast agents or biologic agents.
  • Suicidal behavior or ideation.
  • Children in Care(CiC): a child who has been placed under the control or protection of an agency, organisation, institution or entity by the courts, the government or a government body, acting in accordance with powers conferred on them by law or regulation.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
93 participants (actual)

Study arms

  • Placebo comparator
    Part A: Placebo

    Participants received saline infusion (placebo) intravenously monthly for 48 weeks on a background of standard of care.

    Other: Placebo

  • Experimental
    Part A: Belimumab 10 mg/kg

    Participants received 10 milligrams per kilograms (mg/kg) reconstituted solution intravenously monthly for 48 weeks on a background of standard of care.

    Drug: Belimumab 10 mg/kg

  • Experimental
    Part B: Open-Label Belimumab

    Participants who entered Part B after completing 48 weeks of belimumab or placebo on a background of standard of care and the Week 52 assessments in Part A, received 10 mg/kg belimumab intravenously monthly up to 10 years from the first administration of belimumab.

    Drug: Belimumab 10 mg/kg

  • No intervention
    Part C: Safety Follow-up Phase

    Participants who entered Part C after discontinuing study intervention in Part A or Part B were included in this arm.

Interventions

  • DrugBelimumab 10 mg/kg

    Drug page: Belimumab

    Belimumab was administered.

  • OtherPlacebo

    Placebo was administered

    Also known as: Normal Saline

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With SLE Responder Index (SRI) Response at Week 52

    SRI response is defined as \>=4 point reduction, from Baseline in safety of estrogen in lupus national assessment (SELENA) systemic lupus erythematosus disease activity index (SLEDAI) score, no worsening (increase of \<0.30 points from Baseline) in physician's global assessment (PGA) and no new British Isles Lupus Assessment Group of SLE clinics (BILAG) A organ domain score or 2 new BILAG B organ domain scores compared with Baseline. Analysis was performed using a logistic regression model for the comparison between belimumab and placebo with covariates treatment group, Baseline SELENA SLEDAI score (\<=12 vs. \>=13). Percentage of participants with SRI response at Week 52 of Part A were reported. Intent-to-Treat Population comprised of all participants who were randomized and treated with at least one dose of study agent in Part A. One participant had missing data at Baseline and therefore, could not be included in the analysis.

    Time frame: Week 52

Secondary outcomes

  1. Percentage of Participants Meeting Pediatric Rheumatology International Trials Organization (PRINTO)/ American College of Rheumatology (ACR) Juvenile SLE Response Evaluation Criteria for Improvement in Juvenile SLE at Week 52 Using Definition 1 and 2

    Percentage of participants meeting PRINTO/ACR Juvenile SLE Response Evaluation criteria for improvement in juvenile SLE using two different PRINTO/ACR Juvenile SLE Response Evaluation definitions of improvement that is Definition 1: At least 50% improvement in any 2 of 5 endpoints below and no more than 1 of the remaining worsening by more than 30% and Definition 2: At least 30% improvement in 3 of 5 endpoints below and no more than 1 of the remaining worsening more than 30%. Endpoints were: 1. Percent change in Parent's Global Assessment (ParentGA) at Week 52, 2. Percent change in PGA at Week 52, 3. Percent change in SELENA SLEDAI score at Week 52, 4. Percent change in Pediatric Quality of Life Inventory (PedsQL) physical functioning domain at Week 52, 5. Percent change in 24 hour proteinuria at Week 52 (gram/24hour equivalent by spot urine protein to creatinine ratio).

    Time frame: Week 52

  2. Percent Change From Baseline in ParentGA at Week 52

    ParentGA assesses the participant's overall well-being at the moment rated on a 21-numbered circle visual analog scale (VAS; 0 - very well, 10 - very poorly). Baseline was defined as measurements at Day 0. Percent change from Baseline was calculated by subtracting the Baseline value from value at Week 52 divided by the Baseline value X 100. Last Observation Carried Forward (LOCF) was used. Eight participants had a score of zero at Baseline and therefore, could not be included in the analysis.

    Time frame: Baseline (Day 0) and Week 52

  3. Percent Change From Baseline in PGA at Week 52

    The PGA is a 10 centimeter (cm) visual analogue scale (VAS), anchored at 0 (none) and 3 (severe), designed for the physician to indicate the participant's overall disease activity at a particular visit as part of the validated SELENA SLEDAI index. Primary investigator or a subinvestigator scored the PGA for the participant, and same person evaluated the participant each time. Baseline was defined as measurements at Day 0. Percent change from Baseline was calculated by subtracting the Baseline value from value at Week 52 divided by the Baseline value X 100. LOCF was used.

    Time frame: Baseline (Day 0) and Week 52

  4. Percent Change From Baseline in SELENA SLEDAI at Week 52

    The SELENA SLEDAI score is a weighted index for assessing SLE disease activity in which signs and symptoms, laboratory tests and physician's assessment for each of 9 organ system were given a weighted score and summed if present at the time of the visit or in the preceding 10 days. A SELENA SLEDAI score of 0 would suggest no lupus activity; while a score of 105 is the maximum calculable if all items were scored as being present from active lupus. A decrease of 4 points or more equates to a clinically meaningful improvement. Baseline was defined as measurements at Day 0. Percent change from Baseline was calculated by subtracting the Baseline value from value at Week 52 divided by the Baseline value X 100. One participant had missing data at Baseline and therefore, could not be included in the analysis.

    Time frame: Baseline (Day 0) and Week 52

  5. Percent Change From Baseline in PedsQL Physical Functioning Domain Score at Week 52

    The PedsQL is a generic quality of life scale validated for the pediatric population which consists of 23 items, encompassing 4 health domains: Physical Functioning (8 items), Emotional Functioning (5 items), Social Functioning (5 items), and School Functioning (5 items). From the raw scores of the 23 items, a total summary score and individual domain scores can be calculated. The total and domain scores are each transformed on a 0 to 100 score with higher scores indicating higher quality of life. For Physical Functioning Domain scale, score was from 0 to 100 where, 0 indicates lower quality of life and 100 indicates greater quality of life. Baseline was defined as measurements at Day 0. Percent change from Baseline was calculated by subtracting the Baseline value from value at Week 52 divided by the Baseline Value X 100. LOCF was used.

    Time frame: Baseline (Day 0) and Week 52

  6. Percent Change From Baseline in Proteinuria at Week 52

    Percent change from Baseline in proteinuria was calculated. The percent change from baseline to Week 52 in 24 hour proteinuria was analyzed using summary statistics and 95% confidence intervals, without any adjustment for covariates. Baseline was defined as measurements at Day 0. Percent change from Baseline was calculated by subtracting the Baseline value from value at Week 52 divided by the Baseline Value X 100. LOCF was used.

    Time frame: Baseline (Day 0) and Week 52

  7. Percentage of Participants With a Sustained SRI Response

    Sustained SRI response was defined as having a response on the primary efficacy endpoint at Weeks 44, 48, and 52. Data for percentage of participants with a sustained SRI response was presented. Drop Outs and Treatment Failures were considered Non-Responders. Only those participants with data available at specific time point were analyzed.

    Time frame: Up to 52 weeks

  8. Percentage of Participants With a Sustained ParentGA Response

    Sustained ParentGA response was defined as having \>0.7 improvement at Weeks 44, 48, and 52 compared at Baseline. Data for percentage of participants with a sustained ParentGA response was presented. Thirteen participants had a score of \<=0.7 at Baseline and therefore, could not be included in the analysis.

    Time frame: Up to 52 weeks

  9. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence in a clinical investigation participant, temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or all events of possible drug-induced liver injury with hyperbilirubinemia were categorized as SAE. Number of participants with AEs and SAEs have been reported.

    Time frame: Up to 60 weeks

  10. Maximum Concentration at Steady State (Cmax, ss) and Minimum Concentration at Steady State (Cmin, ss)

    The pharmacokinetic (PK) population comprised all participants included in the As- Treated population for whom at least one post belimumab treatment PK sample was obtained and analyzed. The PK model was fitted to the observed serum concentration-time data. The maximum (Cmax) and minimum (Cmin) concentrations reported in this table are model derived values at ss, assuming a 10 mg/kg dose administered once every 28 days.

    Time frame: 28-days dosing interval at steady state

  11. Area Under Curve of Belimumab at Steady State (AUC, ss)

    The PK model was fitted to the observed serum concentration-time data. The AUC values reported in this table are model derived values at ss, assuming a 10 mg/kg dose administered once every 28 days.

    Time frame: 28-days dosing interval at steady state

07

Results

Posted Aug 15, 2018
Limitations and caveats
This submission adds adverse event data for Parts B and C. The previously posted Part A results are otherwise unchanged, except for a minor cosmetic change. The Statistical Analysis Plan for Part A has not been amended since the 2018 (Part A results) submission. Protocol Amendment 8, included with this submission, has not been amended for Part A of the study.

Participant flow

The study consisted of three parts (Parts A, B, and C). Part A was a parallel-group study where participants could receive either belimumab or placebo. Participants who completed 48 weeks of treatment and Week 52 assessments in Part A could continue to the open label extension phase (Part B) to receive belimumab. Participants who discontinued study intervention in Part A or Part B could enter the long-term safety follow-up phase (Part C).

Part A
Participant flow — Part A
MilestonePart A: PlaceboPart A: Belimumab 10 mg/kgPart B: Open-Label BelimumabPart C: Safety Follow-up Phase
Started405300
Completed314500
Not completed9800
Withdrew: Adverse event5300
Withdrew: Lack of efficacy1100
Withdrew: Physician decision0300
Withdrew: Protocol violation1000
Withdrew: Withdrawal by subject2100
Part B
Participant flow — Part B
MilestonePart A: PlaceboPart A: Belimumab 10 mg/kgPart B: Open-Label BelimumabPart C: Safety Follow-up Phase
Started00750
Completed00190
Not completed00560
Withdrew: Physician decision00140
Withdrew: Adverse event00100
Withdrew: Lack of efficacy00100
Withdrew: Withdrawal by subject00100
Withdrew: Lost to follow-up0020
Withdrew: Protocol violation0010
Withdrew: Long-term follow-up concluded early per pre-defined protocol criteria0090
Part C
Participant flow — Part C
MilestonePart A: PlaceboPart A: Belimumab 10 mg/kgPart B: Open-Label BelimumabPart C: Safety Follow-up Phase
Started00042
Safety population00038
Completed00012
Not completed00030
Withdrew: Withdrawal by subject00016
Withdrew: Physician decision0009
Withdrew: Lost to follow-up0003
Withdrew: Adverse event0002

Outcome measures

PrimaryPercentage of Participants With SLE Responder Index (SRI) Response at Week 52

SRI response is defined as \>=4 point reduction, from Baseline in safety of estrogen in lupus national assessment (SELENA) systemic lupus erythematosus disease activity index (SLEDAI) score, no worsening (increase of \<0.30 points from Baseline) in physician's global assessment (PGA) and no new British Isles Lupus Assessment Group of SLE clinics (BILAG) A organ domain score or 2 new BILAG B organ domain scores compared with Baseline. Analysis was performed using a logistic regression model for the comparison between belimumab and placebo with covariates treatment group, Baseline SELENA SLEDAI score (\<=12 vs. \>=13). Percentage of participants with SRI response at Week 52 of Part A were reported. Intent-to-Treat Population comprised of all participants who were randomized and treated with at least one dose of study agent in Part A. One participant had missing data at Baseline and therefore, could not be included in the analysis.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With SLE Responder Index (SRI) Response at Week 52
Percentage of participantsPart A: PlaceboPart A: Belimumab 10 mg/kg
Percentage of Participants With SLE Responder Index (SRI) Response at Week 5243.652.8
Statistical analysis
  • Part A: Placebo vs Part A: Belimumab 10 mg/kg · Odds ratio (or): 1.49 · 95% CI 0.64 to 3.46
SecondaryPercentage of Participants Meeting Pediatric Rheumatology International Trials Organization (PRINTO)/ American College of Rheumatology (ACR) Juvenile SLE Response Evaluation Criteria for Improvement in Juvenile SLE at Week 52 Using Definition 1 and 2

Percentage of participants meeting PRINTO/ACR Juvenile SLE Response Evaluation criteria for improvement in juvenile SLE using two different PRINTO/ACR Juvenile SLE Response Evaluation definitions of improvement that is Definition 1: At least 50% improvement in any 2 of 5 endpoints below and no more than 1 of the remaining worsening by more than 30% and Definition 2: At least 30% improvement in 3 of 5 endpoints below and no more than 1 of the remaining worsening more than 30%. Endpoints were: 1. Percent change in Parent's Global Assessment (ParentGA) at Week 52, 2. Percent change in PGA at Week 52, 3. Percent change in SELENA SLEDAI score at Week 52, 4. Percent change in Pediatric Quality of Life Inventory (PedsQL) physical functioning domain at Week 52, 5. Percent change in 24 hour proteinuria at Week 52 (gram/24hour equivalent by spot urine protein to creatinine ratio).

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Meeting Pediatric Rheumatology International Trials Organization (PRINTO)/ American College of Rheumatology (ACR) Juvenile SLE Response Evaluation Criteria for Improvement in Juvenile SLE at Week 52 Using Definition 1 and 2
Percentage of participantsPart A: PlaceboPart A: Belimumab 10 mg/kg
Definition 135.060.4
Definition 227.552.8
Statistical analysis
  • Part A: Placebo vs Part A: Belimumab 10 mg/kg · Odds ratio (or): 2.74 · 95% CI 1.15 to 6.54Definition 1
  • Part A: Placebo vs Part A: Belimumab 10 mg/kg · Odds ratio (or): 2.92 · 95% CI 1.19 to 7.17Definition 2
SecondaryPercent Change From Baseline in ParentGA at Week 52

ParentGA assesses the participant's overall well-being at the moment rated on a 21-numbered circle visual analog scale (VAS; 0 - very well, 10 - very poorly). Baseline was defined as measurements at Day 0. Percent change from Baseline was calculated by subtracting the Baseline value from value at Week 52 divided by the Baseline value X 100. Last Observation Carried Forward (LOCF) was used. Eight participants had a score of zero at Baseline and therefore, could not be included in the analysis.

Time frame:
Baseline (Day 0) and Week 52
Reported as:
Median · Percent change
Percent Change From Baseline in ParentGA at Week 52
Percent changePart A: PlaceboPart A: Belimumab 10 mg/kg
Percent Change From Baseline in ParentGA at Week 52-23.61 (-95.0 to 600.0)-53.85 (-100.0 to 900.0)
SecondaryPercent Change From Baseline in PGA at Week 52

The PGA is a 10 centimeter (cm) visual analogue scale (VAS), anchored at 0 (none) and 3 (severe), designed for the physician to indicate the participant's overall disease activity at a particular visit as part of the validated SELENA SLEDAI index. Primary investigator or a subinvestigator scored the PGA for the participant, and same person evaluated the participant each time. Baseline was defined as measurements at Day 0. Percent change from Baseline was calculated by subtracting the Baseline value from value at Week 52 divided by the Baseline value X 100. LOCF was used.

Time frame:
Baseline (Day 0) and Week 52
Reported as:
Mean · Percent change
Percent Change From Baseline in PGA at Week 52
Percent changePart A: PlaceboPart A: Belimumab 10 mg/kg
Percent Change From Baseline in PGA at Week 52-48.802 ± 42.0423-56.525 ± 43.7939
SecondaryPercent Change From Baseline in SELENA SLEDAI at Week 52

The SELENA SLEDAI score is a weighted index for assessing SLE disease activity in which signs and symptoms, laboratory tests and physician's assessment for each of 9 organ system were given a weighted score and summed if present at the time of the visit or in the preceding 10 days. A SELENA SLEDAI score of 0 would suggest no lupus activity; while a score of 105 is the maximum calculable if all items were scored as being present from active lupus. A decrease of 4 points or more equates to a clinically meaningful improvement. Baseline was defined as measurements at Day 0. Percent change from Baseline was calculated by subtracting the Baseline value from value at Week 52 divided by the Baseline value X 100. One participant had missing data at Baseline and therefore, could not be included in the analysis.

Time frame:
Baseline (Day 0) and Week 52
Reported as:
Mean · Percent change
Percent Change From Baseline in SELENA SLEDAI at Week 52
Percent changePart A: PlaceboPart A: Belimumab 10 mg/kg
Percent Change From Baseline in SELENA SLEDAI at Week 52-38.0 ± 39.50-43.3 ± 43.73
SecondaryPercent Change From Baseline in PedsQL Physical Functioning Domain Score at Week 52

The PedsQL is a generic quality of life scale validated for the pediatric population which consists of 23 items, encompassing 4 health domains: Physical Functioning (8 items), Emotional Functioning (5 items), Social Functioning (5 items), and School Functioning (5 items). From the raw scores of the 23 items, a total summary score and individual domain scores can be calculated. The total and domain scores are each transformed on a 0 to 100 score with higher scores indicating higher quality of life. For Physical Functioning Domain scale, score was from 0 to 100 where, 0 indicates lower quality of life and 100 indicates greater quality of life. Baseline was defined as measurements at Day 0. Percent change from Baseline was calculated by subtracting the Baseline value from value at Week 52 divided by the Baseline Value X 100. LOCF was used.

Time frame:
Baseline (Day 0) and Week 52
Reported as:
Median · Percent change
Percent Change From Baseline in PedsQL Physical Functioning Domain Score at Week 52
Percent changePart A: PlaceboPart A: Belimumab 10 mg/kg
Percent Change From Baseline in PedsQL Physical Functioning Domain Score at Week 5212.5 (-53 to 575)10.5 (-100 to 280)
SecondaryPercent Change From Baseline in Proteinuria at Week 52

Percent change from Baseline in proteinuria was calculated. The percent change from baseline to Week 52 in 24 hour proteinuria was analyzed using summary statistics and 95% confidence intervals, without any adjustment for covariates. Baseline was defined as measurements at Day 0. Percent change from Baseline was calculated by subtracting the Baseline value from value at Week 52 divided by the Baseline Value X 100. LOCF was used.

Time frame:
Baseline (Day 0) and Week 52
Reported as:
Median · Percent change
Percent Change From Baseline in Proteinuria at Week 52
Percent changePart A: PlaceboPart A: Belimumab 10 mg/kg
Percent Change From Baseline in Proteinuria at Week 527.0920 (-90.568 to 570.149)-2.1277 (-85.073 to 1681.884)
SecondaryPercentage of Participants With a Sustained SRI Response

Sustained SRI response was defined as having a response on the primary efficacy endpoint at Weeks 44, 48, and 52. Data for percentage of participants with a sustained SRI response was presented. Drop Outs and Treatment Failures were considered Non-Responders. Only those participants with data available at specific time point were analyzed.

Time frame:
Up to 52 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With a Sustained SRI Response
Percentage of participantsPart A: PlaceboPart A: Belimumab 10 mg/kg
Percentage of Participants With a Sustained SRI Response41.043.4
SecondaryPercentage of Participants With a Sustained ParentGA Response

Sustained ParentGA response was defined as having \>0.7 improvement at Weeks 44, 48, and 52 compared at Baseline. Data for percentage of participants with a sustained ParentGA response was presented. Thirteen participants had a score of \<=0.7 at Baseline and therefore, could not be included in the analysis.

Time frame:
Up to 52 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With a Sustained ParentGA Response
Percentage of participantsPart A: PlaceboPart A: Belimumab 10 mg/kg
Percentage of Participants With a Sustained ParentGA Response33.359.1
SecondaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE is any untoward medical occurrence in a clinical investigation participant, temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or all events of possible drug-induced liver injury with hyperbilirubinemia were categorized as SAE. Number of participants with AEs and SAEs have been reported.

Time frame:
Up to 60 weeks
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsPart A: PlaceboPart A: Belimumab 10 mg/kg
AEs3342
SAEs149
SecondaryMaximum Concentration at Steady State (Cmax, ss) and Minimum Concentration at Steady State (Cmin, ss)

The pharmacokinetic (PK) population comprised all participants included in the As- Treated population for whom at least one post belimumab treatment PK sample was obtained and analyzed. The PK model was fitted to the observed serum concentration-time data. The maximum (Cmax) and minimum (Cmin) concentrations reported in this table are model derived values at ss, assuming a 10 mg/kg dose administered once every 28 days.

Time frame:
28-days dosing interval at steady state
Reported as:
Geometric mean · Micrograms per milliliter
Maximum Concentration at Steady State (Cmax, ss) and Minimum Concentration at Steady State (Cmin, ss)
Micrograms per milliliterPart A: Belimumab 10 mg/kg
Cmax, ss315 ± 31.2
Cmin, ss50 ± 68.3
SecondaryArea Under Curve of Belimumab at Steady State (AUC, ss)

The PK model was fitted to the observed serum concentration-time data. The AUC values reported in this table are model derived values at ss, assuming a 10 mg/kg dose administered once every 28 days.

Time frame:
28-days dosing interval at steady state
Reported as:
Geometric mean · Days*micrograms per milliliter
Area Under Curve of Belimumab at Steady State (AUC, ss)
Days*micrograms per milliliterPart A: Belimumab 10 mg/kg
Area Under Curve of Belimumab at Steady State (AUC, ss)3012 ± 43.2

Adverse events

Collected over Part A: From start of study intervention (Day 0) up to Week 60. Part B: From first dose of belimumab (Part A Day 0 for participants randomized to belimumab in Part A; Part A Week 52 for participants randomized to placebo in Part A) up to approximately 10.3 years. Part C: From Part C Day 1 (exit visit from Part A or B, or 28 days after last belimumab infusion in Part B) up to 12 weeks for non-SAEs and up to 10 years for SAEs.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Placebo1/40 (2.5%)14/40 (35%)27/40 (67.5%)
Part A: Belimumab 10 mg/kg0/53 (0%)9/53 (17%)36/53 (67.9%)
Part B: Open-Label Belimumab1/75 (1.3%)30/75 (40%)71/75 (94.7%)
Part C: Safety Follow-up Phase2/38 (5.3%)13/38 (34.2%)3/38 (7.9%)
Most frequent serious events
Showing 10 of 84
Most frequent serious events
EventPart A: PlaceboPart A: Belimumab 10 mg/kgPart B: Open-Label BelimumabPart C: Safety Follow-up Phase
Systemic lupus erythematosusMusculoskeletal and connective tissue disorders0/401/535/753/38
AppendicitisInfections and infestations0/400/531/752/38
HeadacheNervous system disorders2/400/531/750/38
Lupus nephritisRenal and urinary disorders2/402/532/751/38
CellulitisInfections and infestations0/400/533/751/38
GastroenteritisInfections and infestations0/401/533/751/38
Acute kidney injuryRenal and urinary disorders0/400/532/750/38
Autoimmune haemolytic anaemiaBlood and lymphatic system disorders0/400/530/751/38
Febrile neutropeniaBlood and lymphatic system disorders0/400/530/751/38
Cardiac failureCardiac disorders0/400/530/751/38
Most frequent other events
Showing 10 of 65
Most frequent other events
EventPart A: PlaceboPart A: Belimumab 10 mg/kgPart B: Open-Label BelimumabPart C: Safety Follow-up Phase
NasopharyngitisInfections and infestations8/409/5326/753/38
Upper respiratory tract infectionInfections and infestations8/406/5321/750/38
PharyngitisInfections and infestations3/403/5319/750/38
HeadacheNervous system disorders10/407/5316/750/38
GastroenteritisInfections and infestations3/402/5317/750/38
ArthralgiaMusculoskeletal and connective tissue disorders4/403/5316/750/38
Urinary tract infectionInfections and infestations4/401/5313/750/38
AnaemiaBlood and lymphatic system disorders3/400/5312/750/38
NeutropeniaBlood and lymphatic system disorders1/403/5312/750/38
DiarrhoeaGastrointestinal disorders3/407/5312/750/38

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Part A: PlaceboPart A: Belimumab 10 mg/kgTotal
Mean14.8 ± 2.1713.5 ± 2.5914.0 ± 2.49
Sex: Female, Male
Sex: Female, Male(Participants)Part A: PlaceboPart A: Belimumab 10 mg/kgTotal
Female394988
Male145
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A: PlaceboPart A: Belimumab 10 mg/kgTotal
Race customized — White - White/Caucasian/European Heritage212748
Race customized — Asian6814
Race customized — African American/African Heritage235
Race customized — American Indian or Alaskan Native111526
08

Study locations

32 sites
  • GSK Investigational Site
    Phoenix, Arizona 85016, United States
  • GSK Investigational Site
    Washington D.C., District of Columbia 20010, United States
  • GSK Investigational Site
    Augusta, Georgia 30912, United States
  • GSK Investigational Site
    St Louis, Missouri 63104, United States
  • GSK Investigational Site
    New York, New York 10032, United States
  • GSK Investigational Site
    The Bronx, New York 10467, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45229, United States
  • GSK Investigational Site
    Buenos Aires, C1270AAN, Argentina
  • GSK Investigational Site
    Rosario, 2000, Argentina
  • GSK Investigational Site
    Santa Fe, 5400, Argentina
  • GSK Investigational Site
    Calgary, Alberta T3B 6A8, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 1X8, Canada
  • GSK Investigational Site
    Aichi, 474-8710, Japan
  • GSK Investigational Site
    Kagoshima, 890-8520, Japan
  • GSK Investigational Site
    Miyagi, 989-3126, Japan
  • GSK Investigational Site
    Tokyo, 113-8519, Japan
  • GSK Investigational Site
    San Luis Potosí City, 78240, Mexico
  • GSK Investigational Site
    Lima, Lima 27, Peru
  • GSK Investigational Site
    Lima, Lima 5, Peru
  • GSK Investigational Site
    Surco, Lima 33, Peru
  • GSK Investigational Site
    Lodz, 91-738, Poland
  • GSK Investigational Site
    Warsaw, 02-637, Poland
  • GSK Investigational Site
    Moscow, 119435, Russia
  • GSK Investigational Site
    Saint Petersburg, 194100, Russia
  • GSK Investigational Site
    Tolyatti, 445846, Russia
  • GSK Investigational Site
    Espluges de Llobregat, 08950, Spain
  • GSK Investigational Site
    Madrid, 28034, Spain
  • GSK Investigational Site
    Valencia, 46026, Spain
  • GSK Investigational Site
    Bristol, BS2 8BJ, United Kingdom
  • GSK Investigational Site
    Liverpool, L12 2AP, United Kingdom
  • GSK Investigational Site
    London, NW1 2PG, United Kingdom
  • GSK Investigational Site
    London, WC1N 3JH, United Kingdom
09

References and documents

Publications

  • Brunner HI, Abud-Mendoza C, Viola DO, Calvo Penades I, Levy D, Anton J, Calderon JE, Chasnyk VG, Ferrandiz MA, Keltsev V, Paz Gastanaga ME, Shishov M, Boteanu AL, Henrickson M, Bass D, Clark K, Hammer A, Ji BN, Nino A, Roth DA, Struemper H, Wang ML, Martini A, Lovell D, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Ann Rheum Dis. 2020 Oct;79(10):1340-1348. doi: 10.1136/annrheumdis-2020-217101. Epub 2020 Jul 22. PubMed 32699034 ↗
  • Brunner HI, Abud-Mendoza C, Mori M, Pilkington CA, Syed R, Takei S, Viola DO, Furie RA, Navarra S, Zhang F, Bass DL, Eriksson G, Hammer AE, Ji BN, Okily M, Roth DA, Quasny H, Ruperto N. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison. RMD Open. 2021 Sep;7(3):e001747. doi: 10.1136/rmdopen-2021-001747. PubMed 34531304 ↗
  • Zhou X, Lee TI, Zhu M, Ma P. Prediction of Belimumab Pharmacokinetics in Chinese Pediatric Patients with Systemic Lupus Erythematosus. Drugs R D. 2021 Dec;21(4):407-417. doi: 10.1007/s40268-021-00363-2. Epub 2021 Oct 9. PubMed 34628605 ↗
  • Arends EJ, Zlei M, Tipton CM, Cotic J, Osmani Z, de Bie FJ, Kamerling SWA, van Maurik A, Dimelow R, Gregan YI, Fox NL, Rabelink TJ, Roth DA, Sanz I, van Dongen JJM, van Kooten C, Teng YKO. Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2024 Sep 1;63(9):2387-2398. doi: 10.1093/rheumatology/keae286. PubMed 38775637 ↗
  • Hannon CW, McCourt C, Lima HC, Chen S, Bennett C. Interventions for cutaneous disease in systemic lupus erythematosus. Cochrane Database Syst Rev. 2021 Mar 9;3(3):CD007478. doi: 10.1002/14651858.CD007478.pub2. PubMed 33687069 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://d3l8i7lo48obsd.cloudfront.net/gsk-patient-level-data-sharing-july2025-1-Bgwa1UthxvluYbWYTThw.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · d3l8i7lo48obsd.cloudfront.net

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2012 to primary completion in Jan 2018, 64 months.

Results were first posted in Aug 2018, 6 months after primary completion.

Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's 64 months is above that.

Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2012
First posted
Jul 25, 2012
StartActual
Sep 7, 2012
Primary completionActual
Jan 24, 2018
CompletionActual
Sep 30, 2025
Results first posted
Aug 15, 2018
Last update
Apr 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01649765
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 25, 2012
Start date
Sep 7, 2012
Primary completion
Jan 24, 2018
Completion
Sep 30, 2025
Results posted
Aug 15, 2018
Last update
Apr 20, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belimumab

Start the discussion